Late relapse of stage I seminoma following single-agent carboplatin

被引:2
|
作者
Raj, S. [1 ]
Williams, M. V. [1 ]
Dixon, A. K. [1 ]
Robson, J. [1 ]
Mazhar, D. [1 ]
机构
[1] Addenbrookes Hosp, Dept Oncol, Cambridge CB2 0QQ, England
关键词
stage I seminoma; carboplatin;
D O I
10.1159/000136798
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present a case report of a patient who received adjuvant carboplatin for stage 1 seminoma and relapsed with abdominal lymph node metastasis at 48 months. In recent years, many oncologists have offered a single cycle of adjuvant carboplatin AUC7 as adjuvant treatment for stage 1 seminoma. The available data show a non-inferior relapse-free survival at 3 years compared with para-aortic radiotherapy. The rate of relapse beyond this point has not been reported. Patients with stage 1 seminoma represent a group of patients with excellent outcomes, and treatment options must also consider the late effects of treatment, of which there are increasing data of mortality for those treated with radiotherapy. Patients who opt for surveillance have a greater than 80% chance of remaining relapse free at 5 years, but those on surveillance require more CT examinations for follow-up. For those treated with single-agent carboplatin, our case report highlights that late relapse can occur, and we suggest that CT surveillance beyond 2 years is required given the lack of mature data on late relapse. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:419 / 421
页数:3
相关论文
共 50 条
  • [21] Re: Outcome of Men with Relapse after Adjuvant Carboplatin for Clinical Stage I Seminoma
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2017, 198 (03): : 485 - 485
  • [22] Late events in an audit of sequential studies of seminoma receiving single agent carboplatin
    Oliver, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Carboplatin for stage I seminoma and the Sword of Damocles
    Loehrer, PJ
    Bosl, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8566 - 8569
  • [24] Adjuvant treatment of clinical stage I seminoma:: Is a single course of carboplatin sufficient?
    Dieckmann, KP
    Brüggeboes, B
    Pichlmeier, U
    Küster, J
    Müllerleile, U
    Bartels, H
    UROLOGY, 2000, 55 (01) : 102 - 106
  • [25] Adjuvant single agent Carboplatin-therapy for clinical stage I seminoma.: An alternative treatment-option?
    Nöst, G
    Lipsky, H
    Würnschimmel, E
    UROLOGE-AUSGABE A, 1998, 37 (06): : 629 - +
  • [26] Elimination of microscopic metastatases from stage I and II seminoma with single agent, single cycle Carboplatin: A feasible alternative or adjunct to radiotherapy?
    Mason, MD
    Morey, D
    Cole, A
    Griffiths, A
    Gill, P
    BRITISH JOURNAL OF CANCER, 1996, 74 : 24 - 24
  • [27] The prognostic value of LDH in patients with good risk metastatic seminoma treated with single-agent Carboplatin AUC 10
    Aziz, N. Abdul
    Ganguli, S.
    Kenrick, N. G.
    Rajan, P.
    Sharma, A.
    Shamash, J.
    CLINICAL ONCOLOGY, 2025, 38
  • [29] Adjuvant carboplatin treatment for seminoma clinical stage I
    Dieckmann, KP
    Krain, J
    Kuster, J
    Bruggeboes, B
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (01) : 63 - 66
  • [30] Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
    Quah, G. T.
    Espinoza, D.
    Crumbaker, M.
    Balakrishnar, B.
    Arasaratnam, M.
    Bariol, S.
    Brooks, A.
    Lau, H.
    Patel, M.
    Gurney, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1323 - S1323